Drugs / Glecaprevir/pibrentasvir
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT04235049 Comparator | Oct 2021 → Mar 2022 | hepatitis C virus infection | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glecaprevir/pibrentasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04235049 ↗ |